Rimonabant is recommended as an adjunct to diet and exercise in adults who are obese (BMI >30kg/m2) or overweight (BMI >27kg/m) and who have had an inadequate response to, are intolerant of or are contraindicated to orlistat and sibutramine.
The guidance also recommends the following:
- Treatment with rimonabant should continue beyond 6 months only if the patient has lost at least 5% of their body weight since starting treatment.
- Treatment should be discontinued if a patient returns to their original weight while on rimonabant.
- Treatment should not be continued beyond 2 years without a formal clinical assessment and discussion of the risks and benefits with the patient.